Osteoarthritis is a chronic inflammatory disease characterized by cartilage degeneration. Anti-inflammatory therapy has limited effects, and effective reduction of cartilage wear through lubrication is essential. In vivo stability and lubricity of commercial lubricants are insufficient, leading to failure of lubricating treatment and progression of osteoarthritis. To address these issues, new therapeutic methods combining anti-inflammation and stable highperformance lubrication are developed. Inspired by the sliding mechanism of snowboards, a "nano-snowboard" by modifying molybdenum disulfide (MoS 2 ) with a biomimetic phospholipid polymer poly (dopamine methacrylamide-co-2-methacryloyloxyethyl phosphorylcholine) (PDMPC) and loading anti-inflammatory drug diclofenac sodium (DS), namely MoS 2 -PDMPC-DS, has been synthesized. MoS 2 with a 2D layered structure and photothermal properties, serves as solid lubricant and drug carrier. Meanwhile, the modification of PDMPC on the surface of MOS 2 avoids the oxidative denaturation of MoS 2 in a physiological environment, forming solid-liquid composite lubrication and improving the lubricity and stability of MoS 2 in the joint cavity. In vitro and in vivo experiments show that MoS 2 -PDMPC-DS can stay in the joint cavity for more than one week and exert long-lasting lubrication and anti-inflammatory effects to treat osteoarthritis effectively. This solid-liquid composite lubricating nano-snowboard provides a new idea for synergistic anti-inflammatory and lubricating treatment of osteoarthritis.
Non‐invasive light‐based antibacterial therapy has a good prospect in non‐surgical treatment of peri‐implant infections. However, its applications are severely limited by poor penetration of light into human tissues, leading to unsatisfying outcomes. Moreover, as an essential prerequisite for traditional light therapy, lasers can no longer meet the patients’ needs for convenient treatment at any time. To break through the spatial and temporal limitations of traditional light therapy, a wireless‐powered blue‐light zirconia implant for readily available treatment of peri‐implant infection is proposed. In space, complete irradiation to complex peri‐implant structure is realized by the built‐in wireless‐powered light source, thus improving the efficacy. In time, wireless‐powering allows timely and controllable anti‐infection treatment. Blue micro‐light emitting diodes are used as therapeutic light sources, which effectively kill peri‐implant infection‐related bacteria without exogenous photosensitive agents. Porphyromonas gingivalis biofilm on implant surface can be completely killed after 20 min irradiation in vitro. The bactericidal rate of peri‐implant methicillin‐resistant Staphylococcus aureus infection reaches 99.96 ± 0.03% under 30 min per day blue light exposure in vivo. Within the scope of this study, the treatment of peri‐implant infection with blue‐light implant has preliminary feasibility, giving a new approach to non‐invasive treatment of deep oral infections, including peri‐implant infections.
Aim: STING agonists in immunotherapy show great promise and are currently in clinical trials. Combinations of STING agonists with other therapies remain underexplored. This study aimed to combine STING agonist-mediated immunotherapy with photodynamic therapy to treat breast cancer. Methods: STING agonist (ADU-S100)-functionalized porphyrin-based nanoparticles (NP-AS) were prepared and their antitumor properties in terms of cell apoptosis/necrosis and immune activation in triple-negative breast cancer were evaluated. Results: NP-AS induced tumor cell apoptosis/necrosis, activated the innate immune response and exhibited useful antitumor effects. Conclusion: NP-AS effectively treated breast cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.